Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018Jonathan M. Loree, Kanwal Raghav, Seerat Anand et al.|JAMA Oncology|2019Cited by 568
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric‐Bernstam, John D. Hainsworth, Herbert I. Hurwitz et al.|The Lancet Oncology|2019Cited by 564
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract CancersRachna T. Shroff, Mitesh J. Borad, Milind Javle et al.|JAMA Oncology|2019Cited by 472
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trialSalvatore Siena, Takayuki Yoshino, Ki Y. Chung et al.|The Lancet Oncology|2021Cited by 411
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Scott Kopetz, Howard S. Höchster, Katherine A. Guthrie et al.|Journal of Clinical Oncology|2020Cited by 391